Intravitreal Pharmacotherapy for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: A Narrative Review

Hamidreza Torabi

Abstract


Branch retinal vein occlusion (BRVO) is the next most common retinal vascular disorder following diabetic retinopathy, and macular edema is the most frequent cause of visual impairment in patients with BRVO. For many years, grid laser photocoagulation was the standard of care for the treatment of BRVO-associated macular edema. Grid laser photocoagulation was used for patients with macular edema secondary to BRVO longer than 3 months and visual acuity less than 20/40. Currently increasing data supports the effect of anti-vascular endothelial growth factors in the treatment of BRVO-associated macular edema. Recent studies have shown that intravitreal bevacizumab injection is a safe and effective modality for the treatment of BRVO-associated macular edema; however, the recurrence of macular edema is common following an intravitreal bevacizumab injection. Other anti-vascular endothelial growth factor (VEGF) agents such as ranibizumab, pegaptanib, and aflibercept are effective options. Combining anti-VEGFS with grid laser may be effective in refractory cases and also may prolong the interval between intravitreal injections. Switching to a different anti-VEGF or dexamethasone implant may be effective in the treatment of refractory cases; however, the efficacy of an intravitreal dexamethasone implant may diminish after a few months, and elevated intraocular pressure and cataract formation may occur.

Keywords


Branch Retinal Vein Occlusion, Macular Edema, Anti-VEGF, Intravitreal Injection

Full Text:

PDF

References


Orth DH, Patz A. Retinal branch vein occlusion. Surv Ophthalmol. 1978;22(6):357-376. doi:10.1016/0039-6257(78)90132-7.

McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1113-1123.e1115. doi:10.1016/j.ophtha.2010.01.060.

Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24:493-519. doi:10.1016/j.preteyeres.2004.12.001.

Bertelsen M, Linneberg A, Rosenberg T, Christoffersen N, Vorum H, GadeE, Larsen M. Comorbidity in patients with branch retinal vein occlusion: case-control study. BMJ. 2012;345:e7885. doi:10.1136/bmj.e7885.

Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114(10):1243-1247. doi:10.1001/archopht.1996.01100140443012.

Regnier SA, Larsen M, Bezlyak V, Allen F. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open. 2015;5(6):e007527. doi:10.1136/bmjopen-2014-007527.

Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;19(3):234-238. doi:10.1097/ICU.0b013e3282fb7fb0.

Greer DV, Constable IJ, Cooper RL. Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol. 1980;8(3):207-209. doi:10.1111/j.1442-9071.1980.tb00340.x.

Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-319.e311. doi:10.1016/j.ophtha.2009.07.017.

Risk factors for branch retinal vein occlusion. The Eye Disease Case-control Study Group. Am J Ophthalmol. 1993;116(3):286-296. doi:10.1016/S0002-9394(14)71345-5.

Kumar B, Yu DY, Morgan WH, Barry CJ, Constable IJ, McAllister IL. The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology. 1998;105(3):424-427. doi:10.1016/S0161-6420(98)93022-6.

Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984;98(3):271-282. doi:10.1016/0002-9394(84)90316-7.

Aref AA, Scott IU. Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update. Adv Ther. 2011;28(1):28-39. doi:10.1007/s12325-010-0089-3.

Shilling JS, Jones CA. Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol. 1984;68(3):196-198. doi:10.1136/bjo.68.3.196.

Battaglia Parodi M, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1999;237(12):1024-1027. doi:10.1007/s004170050339.

Battaglia Parodi M, Saviano S, Bergamini L, Ravalico G. Grid laser treatment of macular edema in macular branch retinal vein occlusion. Doc Ophthalmol. 1999;97(3-4):427-431. doi:10.1023/A:1002452004743.

Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140(2):256-261. doi:10.1016/j.ajo.2005.03.003.

Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363(22):2135-2144. doi:10.1056/NEJMcp1003934.

Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation cystoid macular edema in branch retinal vein occlusion. Retina. 2009;29(4):511-515. doi: 10.1097/IAE.0b013e318195ca65.

Leitritz MA, Gelisken F, Ziemssen F, Szurman P, Bartz-Schmidt KU, Jaissle GB. Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol. 2013;97(2):215-219. doi: 10.1136/bjophthalmol-2012-301992.

Parveen S, Narayanan R, Sambhav K, Bhatia K. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2010;30(8):1324-1325; author reply 1325. doi:10.1097/IAE.0b013e3181e723c7.

Donati S, Barosi P, Bianchi M, Al Oum M, Azzolini C. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol. 2012;22(4):607-614. doi:10.5301/ejo.5000085.

Salinas-Alaman A, Zarranz-Ventura J, Caire Gonzalez-Jauregui JM, Sadaba-Echarri LM, Barrio-Barrio J, Garcia-Layana A. Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol. 2011;21(4):434-439. doi:10.5301/EJO.2010.6101.

Ogino K, Tsujikawa A, Murakami T, Muraoka Y, Kurashige Y, Yoshimura N. Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion. Clin Ophthalmol. 2011;5:1031-1036. doi:10.2147/OPTH.S22923.

Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina. 2009;29(10):1396-1403. doi:10.1097/IAE.0b013e3181bcef53.

Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina. 2007;27(4):426-431. doi:10.1097/IAE.0b013e31804a7af2.

Yasuda S, Kondo M, Kachi S, et al. Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion. Retina. 2011;31(6):1075-1082. doi:10.1097/IAE.0b013e318206cf4b.

Khan MA, Mallika V, Joshi D. Comparison of immediate versus deferred intravitreal Bevacizumab in macular oedema due to branch retinal vein occlusion: a pilot study. Int Ophthalmol. 2017. doi:10.1007/s10792-017-0538-y.

Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16(4):791-799. doi:10.1038/mt.2008.10.

Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.e1101. doi:10.1016/j.ophtha.2010.02.021.

Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-1602. doi:10.1016/j.ophtha.2011.02.022.

Karagiannis DA, Karampelas MD, Soumplis VM, Amariotakis C, Georgalas I, Kandarakis A. Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (Lucentis). Can J Ophthalmol. 2011;46(6):486-490. doi:10.1016/j.jcjo.2011.09.014.

Hladíková Z, Klofacova E, Kalvodova B. [Two-Year Follow-up Results of Patients with Macular Oedema Due to Retinal Vein Occlusion Treated with Ranibizumab]. Cesk Slov Oftalmol. 2017;73(2):43-51.

Son BK, Kwak HW, Kim ES, Yu SY. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion. Korean J Ophthalmol. 2017;31(3):209- 216. doi:10.3341/kjo.2015.0158.

Sugiura Y, Okamoto F, Morikawa S, Okamoto Y, Hiraoka T, Oshika T. Time course of changes in metamorphopsia following intravitreal ranibizumab injection for branch retinal vein occlusion. Retina. 2017. doi:10.1097/IAE.0000000000001740.

Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816. doi:10.1056/ NEJMoa042760.

Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology. 2011;118(6):1107-1118. doi:10.1016/j.ophtha.2011.02.045.

Gonzalez VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol. 2009;93(11):1474-1478. doi:10.1136/bjo.2008.155663.

Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006;113(1):23-28. doi:10.1016/j.ophtha.2005.10.012.

Wroblewski JJ, Wells JA 3rd, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009;127(4):374-380. doi:10.1001/archophthalmol.2009.14.

Udaondo P, Garcia-Delpech S, Salom D, Garcia-Pous M, Diaz- Llopis M. Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion. Clin Ophthalmol. 2011;5:941- 944. doi:10.2147/OPTH.S18873.

Wroblewski JJ, Wells JA, 3rd, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol. 2010;149(1):147-154. doi:10.1016/j.ajo.2009.08.005.

Kaldirim HE, Yazgan S. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Int Ophthalmol. 2017. doi:10.1007/s10792-017-0618-z.

Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538-544. doi:10.1016/j.ophtha.2014.08.031.

Sakanishi Y, Usui-Ouchi A, Tamaki K, Mashimo K, Ito R, Ebihara N. Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab. Clin Ophthalmol. 2017;11:829-834. doi:10.2147/OPTH.S133594.

Tagami M, Sai R, Fukuda M, Azumi A. Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion. Clin Ophthalmol. 2017;11:403-408. doi:10.2147/OPTH.S128651.

Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128. doi:10.1001/archophthalmol.2009.233.

Ozkiris A, Evereklioglu C, Erkilic K, Dogan H. Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye (Lond). 2006;20(1):13-17. doi:10.1038/sj.eye.6701803.

Ramezani A, Entezari M, Moradian S, et al. Intravitreal triamcinolone for acute branch retinal vein occlusion: a randomized clinical trial. J Ophthalmic Vis Res. 2011;6(2):101-108.

Coscas G, Loewenstein A, Augustin A, et al. Management of retinal vein occlusion--consensus document. Ophthalmologica. 2011;226(1):4-28. doi:10.1159/000327391.

Lattanzio R, Torres Gimeno A, Battaglia Parodi M, Bandello F. Retinal vein occlusion: current treatment. Ophthalmologica. 2011;225(3):135-143. doi:10.1159/000314718.

Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2005;139(6):972-982. doi:10.1016/j.ajo.2004.12.087.

Ehrlich R, Ciulla TA, Moss AM, Harris A. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol. 2010;248(3):375-380. doi:10.1007/s00417-009-1211-6.

Moon J, Kim M, Sagong M. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye (Lond). 2016;30(8):1084-1090. doi:10.1038/eye.2016.96.

Robinson MR, Whitcup SM. Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev Clin Pharmacol. 2012;5(6):629-647. doi:10.1586/ecp.12.55.

Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453-2460. doi:10.1016/j.ophtha.2011.05.014.

Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond). 2013;27(1):65-71. doi:10.1038/eye.2012.226.

Dugel PU, Capone Jr A, Singer MA, et al. Two or more dexamethasone intravitreal implants in treatment-naive patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol. 2015;15:118. doi:10.1186/s12886-015-0106-z.

Joshi L, Yaganti S, Gemenetzi M, et al. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol. 2013;97(8):1040- 1044. doi:10.1136/bjophthalmol-2013-303207.

Augustin AJ, Holz FG, Haritoglou C, et al. Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica. 2015;233(1):18-26. doi:10.1159/000368840.

Bandello F, Parravano M, Cavallero E, et al. Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmic Res. 2015;53(4):207-216. doi:10.1159/000381187.

Querques L, Querques G, Lattanzio R, et al. Repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmologica. 2013;229(1):21-25. doi:10.1159/000342160.

Singer MA, Bell DJ, Woods P, et al. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina. 2012;32(7):1289- 1294. doi:10.1097/IAE.0b013e318242b838.

Yuksel B, Karti O, Celik O, Kerci SG, Kusbeci T. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion. Clin Exp Optom. 2017. doi:10.1111/cxo.12586.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Creative Commons License
International Journal of Medical Reviews is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.